

## ENVISION Haiti

### TREATING 5.1 MILLION PEOPLE ANNUALLY FOR NEGLECTED TROPICAL DISEASES

#### FUNDING LEVEL

\$10 million • 2011 – 2016

#### DONORS

USAID

#### PARTNERS

RTI International, Ministry of Health and Population (MSPP), Ministry of Education (MENFP)

#### KEY ACHIEVEMENTS

- Conduct annual MDA treatment, technical assistance for monitoring and evaluation, capacity building of community volunteers, and increased community advocacy and social mobilization to develop NTD awareness.
- Treat 5.1 million Haitians annually for lymphatic filariasis and soil-transmitted helminthes.
- Train nearly 20,000 community leaders, promoters, and drug distributors annually.
- 91 USAID-supported communes have reached six rounds of consecutive MDA, and 75 evaluation units will be eligible for Stop-MDA Transmission Assessment Surveys, edging Haiti closer to its disease elimination goals.
- Public-private partnership with TOMS Shoes (an American footwear company) to provide children with hundreds of thousands of pairs of shoes, which are the first line of defense against STH infection.

#### BACKGROUND

Approximately 1 billion people globally are affected by one or more neglected tropical diseases (NTDs). The USAID-funded ENVISION Project contributes to the international goal of reducing the public health burden of targeted diseases by providing assistance to national programs for the control and elimination of seven targeted NTDs: lymphatic filariasis (LF), onchocerciasis, schistosomiasis, trachoma, and three types of soil-transmitted helminthes (STH).



*IMA World Health (IMA) partners with the Ministry of Health and Population and the Ministry of Education to treat 5.1 million Haitians annually for lymphatic filariasis and soil-transmitted helminthes.*

Since 1998, IMA World Health has been working in Haiti to combat LF and STH, and since 2011 has been the lead implementing partner of the ENVISION Project in Haiti.

#### PROJECT APPROACH

The Haiti NTD Control Program (HNTDCP) is a joint effort between the Ministry of Health and Population (MSPP) and the Ministry of Education (MENFP) to eliminate LF and control STH infection. In addition, IMA has been working closely with the HNTDCP to build its capacity to implement mass drug administration (MDA) and conduct monitoring and evaluation of program activities. IMA leads collaboration with the HNTDCP for MDA of diethylcarbamazine (DEC) and Albendazole to prevent LF and control STH, respectively. IMA support has helped the HNTDCP move closer to its goal of LF elimination by 2020.